Successful tyrosine kinase inhibitor discontinuation outside clinical trials — data from the population‐based Swedish chronic myeloid leukaemia registry
Hjalmar Flygt(Uppsala University Hospital), Johan Richter(Skåne University Hospital), Martin Höglund(Uppsala University Hospital), Berit Markevärn, Ulla Olsson‐Strömberg(Uppsala University Hospital), Stina Söderlund(Uppsala University Hospital), Anna Lübking(Skåne University Hospital), Fredrik Sandin(Regional Research Council in Uppsala-Örebro Region), Kristina Myhr‐Eriksson(Sunderby sjukhus), Anders Själander(Umeå University), Karin Olsson(Regional Research Council in Uppsala-Örebro Region), Hans Wadenvik, Torsten Dahlén(Karolinska University Hospital), Leif Stenke(Karolinska Institutet), Lovisa Wennström(Sahlgrenska University Hospital), Arta Dremaine(Linköping University Hospital)
Cited by 15
Related Papers
Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
|New England Journal of Medicine|2014|3.5k
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
|Blood|2013|632
Thalassemia Syndromes
|Unknown|2009|475